Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$354.26M$354.26M+22.1% vs Q3 2024 Net Income$175.23M$175.23M+27.9% vs Q3 2024 EPS Diluted$1.43$1.43+36.2% vs Q3 2024 Operating Income$217,921,000+33.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$175,567,000+54.2% Margins · derivedOperating margin61.5%+5.3 pt vs Q3 2024
Net margin49.5%+2.2 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 3, 2025 · 34 d after period end